These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38346146)

  • 1. The influence of dead space in blood sampling needle on FVIII level and pharmacokinetic profiles in children with hemophilia.
    Zhen Y; Ai D; Huang K; Li G; Chen Z; Wu R
    Hematology; 2024 Dec; 29(1):2314871. PubMed ID: 38346146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.
    Chen ZP; Li PJ; Li G; Tang L; Zhen YZ; Wu XY; Cheng XL; Luke KH; Blanchette VS; Poon MC; Ding QL; Wu RH
    Chin Med J (Engl); 2018 Aug; 131(15):1780-1785. PubMed ID: 29848837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A.
    Chen Z; Huang K; Li G; Zhen Y; Wu X; Di A; Liu G; Li Z; Alfonso I; Wu R
    Pediatr Investig; 2021 Mar; 5(1):38-45. PubMed ID: 33778426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users.
    McEneny-King A; Yeung CH; Edginton AN; Iorio A; Croteau SE
    Haemophilia; 2020 Jan; 26(1):56-63. PubMed ID: 31742831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
    Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
    J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A.
    Huang K; Wang Y; Zhen Y; Li G; Wu X; Zhang N; Chen Z; Wu R
    Thromb Res; 2022 May; 213():71-77. PubMed ID: 35305529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
    Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
    J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic study of Kovaltry in thirty-five pediatric patients aged <12 years with severe hemophilia A.
    Huang K; Zhen Y; Li G; Wu X; Wu R; Chen Z
    Haemophilia; 2021 May; 27(3):e340-e346. PubMed ID: 33645868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards.
    Morfini M; Cinotti S; Bellatreccia A; Paladino E; Gringeri A; Mannucci PM;
    J Thromb Haemost; 2003 Nov; 1(11):2283-9. PubMed ID: 14629459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
    Gringeri A; Wolfsegger M; Steinitz KN; Reininger AJ
    Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects.
    Blanchette VS; Zunino L; Grassmann V; Barnes C; Carcao MD; Curtin J; Jackson S; Khoo L; Komrska V; Lillicrap D; Morfini M; Romanova G; Stephens D; Zapotocka E; Rand ML; Blatny J
    Thromb Haemost; 2021 Oct; 121(10):1326-1336. PubMed ID: 33506480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
    Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
    J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic profile of children with haemophilia A receiving low-dose FVIII prophylaxis in Indonesia: A single centre experience.
    Primacakti F; Sari TT; Gatot D; Sjakti HA; Chozie NA
    Haemophilia; 2022 Sep; 28(5):720-725. PubMed ID: 35537097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C).
    Shima M; Matsumoto T; Fukuda K; Kubota Y; Tanaka I; Nishiya K; Giles AR; Yoshioka A
    Thromb Haemost; 2002 Mar; 87(3):436-41. PubMed ID: 11916076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.
    Swystun LL; Ogiwara K; Rawley O; Brown C; Georgescu I; Hopman W; Labarque V; Male C; Thom K; Blanchette VS; Carcao MD; Lillicrap D
    Blood; 2019 Sep; 134(11):880-891. PubMed ID: 31350267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
    Björkman S; Blanchette VS; Fischer K; Oh M; Spotts G; Schroth P; Fritsch S; Patrone L; Ewenstein BM; ; Collins PW
    J Thromb Haemost; 2010 Apr; 8(4):730-6. PubMed ID: 20398185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
    Solms A; Shah A; Berntorp E; Tiede A; Iorio A; Linardi C; Ahsman M; Mancuso ME; Zhivkov T; Lissitchkov T
    Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A ROTEM method using APTT reagent and tissue factor as the clotting activators may better define bleeding heterogeneity in moderate or severe haemophilia A (part I: Study in plasma samples).
    He S; Eelde A; Petrini P; Wallen H; Gabrielsson L; Svensson J; Blombäck M; Holmström M
    Thromb Res; 2018 Nov; 171():7-13. PubMed ID: 30216822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.
    Preijers T; van Moort I; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA;
    Thromb Haemost; 2018 Mar; 118(3):514-525. PubMed ID: 29534249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.